Provectus Biopharmaceuticals Inc (PVCT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 12-2021 | 09-2021 | 06-2021 | 03-2021 | 12-2020 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -5,540 | -4,301 | -3,250 | -1,670 | -6,678 |
| Depreciation Amortization | 13 | 10 | 6 | 3 | 242 |
| Accounts payable and accrued liabilities | 331 | 303 | 252 | -11 | -170 |
| Other Working Capital | 4,472 | 1,633 | 1,425 | 514 | 2,142 |
| Other Operating Activity | -289 | -280 | -254 | 51 | 379 |
| Operating Cash Flow | $-1,013 | $-2,635 | $-1,820 | $-1,114 | $-4,086 |
| Cash Flows From Investing Activities | |||||
| Investing Cash Flow | $N/A | $N/A | $N/A | $N/A | $N/A |
| Cash Flows From Financing Activities | |||||
| Change In Short Term Borrowing | N/A | N/A | -85 | -74 | 63 |
| Debt Issued | 3,160 | 1,900 | 1,700 | 1,200 | 3,225 |
| Common Stock Issued | 962 | 962 | 251 | 240 | 419 |
| Other Financing Activity | -98 | -69 | -95 | 0 | -106 |
| Financing Cash Flow | $4,024 | $2,793 | $1,770 | $1,365 | $3,600 |
| Exchange Rate Effect | -1 | -1 | 0 | 1 | -8 |
| Beginning Cash Position | 97 | 97 | 97 | 97 | 591 |
| End Cash Position | 3,107 | 254 | 47 | 350 | 97 |
| Net Cash Flow | $3,010 | $157 | $-50 | $253 | $-494 |
| Free Cash Flow | |||||
| Operating Cash Flow | -1,013 | -2,635 | -1,820 | -1,114 | -4,086 |
| Free Cash Flow | -1,013 | -2,635 | -1,820 | -1,114 | -4,086 |